Latest Regulatory News

Dimerix Limited’s ACTION3 Phase 3 trial for DMX-200 in FSGS kidney disease has passed its seventh Independent Data Monitoring Committee review with no safety concerns, reinforcing the drug’s promising safety profile.

Horizon Oil Limited reported robust FY25 results, highlighted by a strategic acquisition of Thailand upstream assets and a 10-year permit extension at Maari, nearly doubling production and securing a strong outlook through 2030.

Red Mountain Mining Ltd has made a strong entrance on the US OTCQB market, surging 36% on its first day of trading as it advances key antimony and gold projects across the US and Australia.

Prescient Therapeutics has achieved a key regulatory milestone with the European Medicines Agency granting Orphan Drug Designation for its PTX-100 therapy targeting Cutaneous T-cell Lymphomas, enhancing its commercial and clinical prospects in Europe.

Middle Island Resources has identified significant lead and zinc soil anomalies at the Tisovik target within its Bobija Project in Serbia, highlighting promising exploration potential in a historically mined area. Assay results reveal high-grade mineralisation footprints extending over 1.5km, setting the stage for further investigation.

Talga Group has received official land allocation approval for its Nunasvaara Södra graphite mine in Sweden, a critical step in advancing its sustainable battery materials project.

Enegex Limited has completed its acquisition of Famien Resources and appointed Paul Roberts as Managing Director, signaling a strategic shift aimed at accelerating gold exploration efforts.

TPG Telecom has successfully raised $300 million through its institutional reinvestment plan, issuing new shares at a discount to offset recent capital returns and strengthen its balance sheet. The plan faced adjustments due to a tragic incident and volatile market conditions.

Osmond Resources has reported exceptional assay results from its first drill hole at the Orión EU Critical Minerals Project, confirming high-grade titanium, zircon, and rare earth mineralisation. The discovery positions the project as a significant potential supplier of critical minerals within the EU.

BCAL Diagnostics is preparing to launch its Avantect® pancreatic and ovarian cancer blood tests in Australia by January 2026, following key regulatory approvals and promising clinical data. The company also broadens the reach of its BREASTESTplus™ breast cancer test, targeting a larger segment of women with dense breast tissue.

Decidr AI Industries has announced a strategic acquisition of Delaware-based Sugarwork Inc., marking its official entry into the US market and enhancing its Agentic AI platform with advanced knowledge transfer capabilities.

Cyclopharm Limited reaffirms its ambitious target of 250–300 US Technegas installations by late 2026, driven by FDA approval, CMS reimbursement, and a growing pipeline of healthcare sites. The company reports record half-year revenue growth, signaling strong momentum in the expanding lung imaging market.